Shanghai Henlius Biotech Inc logo

2696 - Shanghai Henlius Biotech Inc Share Price

HK$40.95 -0.7  -1.6%

Last Trade - 23/10/20

Sector
Healthcare
Size
Mid Cap
Market Cap £2.20bn
Enterprise Value £2.14bn
Revenue £21.1m
Position in Universe 453rd / 6000
Bullish
Bearish
Unlock 2696 Revenue
Momentum
Relative Strength (%)
1m -21.1%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -38.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 33.9 7.42 90.9 661.6 1,663 +63.8%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Shanghai Henlius Biotech Inc revenues totaled RMB110.4M. Net loss totaled to RMB448M. Results are not comparable due to year end change.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for 2696
Graphical History

Revenue

2696 Revenue Unlock 2696 Revenue

Net Income

2696 Net Income Unlock 2696 Revenue

Normalised EPS

2696 Normalised EPS Unlock 2696 Revenue

PE Ratio Range

2696 PE Ratio Range Unlock 2696 Revenue

Dividend Yield Range

2696 Dividend Yield Range Unlock 2696 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
2696 EPS Forecasts Unlock 2696 Revenue
Profile Summary

Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
No. of Shareholders: n/a
No. of Employees: 1,629
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Stock Exchange of Hong Kong Limited
Shares in Issue 543,494,853
Free Float (0.0%)
Eligible for
ISAs
SIPPs
2696 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 2696
Upcoming Events for 2696
Thursday 19th November, 2020
Shanghai Henlius Biotech Inc Extraordinary Shareholders Meeting
Frequently Asked Questions for Shanghai Henlius Biotech Inc
What is the Shanghai Henlius Biotech Inc share price?

As of 23/10/20, shares in Shanghai Henlius Biotech Inc are trading at HK$40.95, giving the company a market capitalisation of £2.20bn. This share price information is delayed by 15 minutes.

How has the Shanghai Henlius Biotech Inc share price performed this year?

Shares in Shanghai Henlius Biotech Inc are currently trading at HK$40.95 and the price has moved by -9% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Shanghai Henlius Biotech Inc price has moved by -9.6% over the past year.

What are the analyst and broker recommendations for Shanghai Henlius Biotech Inc?

There are no analysts currently covering Shanghai Henlius Biotech Inc.

When will Shanghai Henlius Biotech Inc next release its financial results?

Shanghai Henlius Biotech Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Shanghai Henlius Biotech Inc dividend yield?

Shanghai Henlius Biotech Inc does not currently pay a dividend.

Does Shanghai Henlius Biotech Inc pay a dividend?

Shanghai Henlius Biotech Inc does not currently pay a dividend.

When does Shanghai Henlius Biotech Inc next pay dividends?

Shanghai Henlius Biotech Inc does not currently pay a dividend.

How do I buy Shanghai Henlius Biotech Inc shares?

To buy shares in Shanghai Henlius Biotech Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Shanghai Henlius Biotech Inc?

Shares in Shanghai Henlius Biotech Inc are currently trading at HK$40.95, giving the company a market capitalisation of £2.20bn.

Where are Shanghai Henlius Biotech Inc shares listed? Where are Shanghai Henlius Biotech Inc shares listed?

Here are the trading details for Shanghai Henlius Biotech Inc:

Country of listing: Hong Kong
Exchange: HKG
Ticker Symbol: 2696
What kind of share is Shanghai Henlius Biotech Inc?

Based on an overall assessment of its quality, value and momentum, Shanghai Henlius Biotech Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Shanghai Henlius Biotech Inc share price forecast 2020?

Shares in Shanghai Henlius Biotech Inc are currently priced at HK$40.95. At that level they are trading at 44.91% discount to the analyst consensus target price of 0.00.

Analysts covering Shanghai Henlius Biotech Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.3686323779 for the next financial year.

How can I tell whether the Shanghai Henlius Biotech Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shanghai Henlius Biotech Inc. Over the past six months, the relative strength of its shares against the market has been -26.91%. At the current price of HK$40.95, shares in Shanghai Henlius Biotech Inc are trading at -10.06% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Shanghai Henlius Biotech Inc PE Ratio?

We were not able to find PE ratio data for Shanghai Henlius Biotech Inc.

Who are the key directors of Shanghai Henlius Biotech Inc?

We were unable to find the directors for Shanghai Henlius Biotech Inc.

Who are the major shareholders of Shanghai Henlius Biotech Inc?

Here are the top five shareholders of Shanghai Henlius Biotech Inc based on the size of their shareholding:

Henlius Biopharmaceuticals, Inc. Corporation
Percentage owned: 36.09% (59.0m shares)
Qatar Investment Authority Sovereign Wealth Fund
Percentage owned: 8.7% (14.2m shares)
China International Capital Corporation Hong Kong Asset Mana Investment Advisor/Hedge Fund
Percentage owned: 4.74% (7.75m shares)
AVICT Global Holdings Ltd. Corporation
Percentage owned: 2.9% (4.74m shares)
Baron Capital Management, Inc. Investment Advisor/Hedge Fund
Percentage owned: 2.25% (3.67m shares)
Similar to 2696
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.